Adam Giermasz, M.D., Ph.D.
Benign and Malignant Hematology
- Associate Professor (HSCP)
Philosophy of Care
My Philosophy is to educate my patients and their families so they may participate fully in decisions about their care. I strive to care in an environment that is open and accepting.
Adam Giermasz co-directs the Hemophilia Treatment Center. He specializes in hemophilia, coagulation and thrombosis disorders.
Dr. Giermasz' research includes studies in new therapeutics with use of next generation clotting factor, bypassing agents and gene therapy; in addition he is interested in clinical projects aiming for quality of life improvement in patients with bleeding disorders.
Hematology and Oncology
M.D., Medical University of Warsaw, Warsaw, Poland 1998
Ph.D., Medical University of Warsaw, Warsaw, Poland 2002
B.S., III Secondary School - Lyceum, Warsaw, Poland 1992
Internship: Medicine, Military School of Medicine, Warsaw, Poland 1998-1999
Internship: Medicine, University of Pittsburgh Medical Center, Pittsburgh PA 2005-2006
Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh PA 2006-2008
Hematology Oncology, UC San Francisco Medical Center, San Francisco CA 2008-2011
American Board of Internal Medicine,
American Board of Internal Medicine, Hematology,
American Society of Hematology
American Society of Hematology (ASH)
International Society on Thrombosis and Haemostasis
Honors and Awards
Top 10 Clinical Research Achievement Award for coauthored NEJM publication: "Hemophilia B Gene Therapy�, 2019
Annual Teaching Award, Medical University of Warsaw, 2000
National award and grant for young scholars of The Foundation for Polish Science (FNP), 2000
Scientific Award, Medical University of Warsaw, 1998
Select Recent Publications
To view a detailed list of Dr. Giermasz's publications, please click here.
Escobar MA, Tehranchi R, Karim FA, Caliskan U, Chowdary P, Colberg T, Giangrande P, Giermasz, A, Mancuso ME, Serban M, Tsay W, Mahlangu JN. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017 Jan;23(1):67-76. doi:10.1111/hae.13041. Epub 2016 Aug 1.
Kono M, Nakamura Y, Suda T, Uchijima M, Tsujimura K, Nagata T, Giermasz, AS, Kalinski P, Nakamura H, Chida K. Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine. Vaccine. 2012 Mar 30;30(16):2633-9. doi:10.1016/j.vaccine.2012.02.026. Epub 2012 Feb 22.
Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, Kalinski P. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother. 2010 Aug;58(8):1329-1336. Published online 2009 Jan 21. doi:10.1007/s00262-008-0648-5.
Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, Hendricks RL, Kalinski P. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Research. 2007 Oct 15;67(20):10012-8. doi:10.1158/0008-5472.CAN-07-1735.
Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunologic Research. 2006;36(1-3):137-46. doi:10.1385/IR:36:1:137.
Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB. Natural killer-dendritic cell cross-talk in cancer mmunotherapy. Expert Opin Biol Ther. 2005 Oct;5(10):1303-15. doi:10.1517/14712522.214.171.1243.
Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol. 2005 Feb;42(4):535-9. doi:10.1016/j.molimm.2004.07.038.
Stoklosa T, Golab J, Wójcik C, Wlodarski P, Jalili A, Januszko P, Giermasz A, Wilczynski GM, Pleban E, Marczak M, Wilk S, Jakóbisiak M. Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor. APOPTOSIS. 2004 Feb 29;9(2):193-204. doi:10.1023/b:appt.0000018801.59062.1d. PMID:15004516.
Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol. 2003 Sep 1;171(5): 2366-73. doi:10.4049/jimmunol.171.5.2366.
O'Connell PJ, Son YI, Giermasz A, Wang Z, Logar AJ, Thomson AW, Kalinski P. Type-1 polarized nature of mouse liver CD8alphaand CD8alpha+ dendritic cells: tissue-dependent differences offset CD8alpha-related dendritic cell heterogeneity. Eur J Immunol. 2003 Jul;33(7):2007-13. doi:10.1002/eji.200323379.